Researcher
Kristel Van Calsteren
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Woman and Child (Division)
Member
From1 Apr 2013 → Today - Department of Development and Regeneration (Department)
Member
From1 Oct 2012 → 31 Mar 2013 - Gynaecological Oncology (Division)
Member
From1 Nov 2009 → 31 Aug 2011
Projects
1 - 10 of 12
- Perinatal depression in (pregnant) mothers: 'From prevalence to prevention' – A precision medicine approach within a public health perspectiveFrom1 Oct 2022 → TodayFunding: BOF - projects, Fund Recuperation Fiscal Exemption
- The development and validation of a prototype of a Belgian data registration system on medication use during pregnancy and lactation (BELpREG-project)From1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Cancer in pregnancy: Longitudinal follow-up of child development after prenatal exposure to maternal cancerFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The impact of an international advisory board on the management of cancer during pregnancyFrom11 Mar 2020 → 11 Mar 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- IMPLEMENTATION OF GENOME-WIDE CELL-FREE DNA SEQUENCING FOR THE EARLY IDENTIFICATION AND EFFICIENT MANAGEMENT OF HIGH-RISK PREGNANCIESFrom1 Nov 2019 → 10 Oct 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Cancer treatment during pregnancy.From1 Jan 2019 → 31 Dec 2022Funding: Nonprofit institution or equivalents
- Antenatal Sildenafil To Prevent Pulmonary hypertension in congenital diaphragmatic Hernia (SToP-PH): moving from bench to clinical practiceFrom1 Oct 2017 → 30 Sep 2019Funding: IOF - Industrial Research Fund
- PROGNOSTIC FACTORS FOR OBSTETRIC AND ONCOLOGICAL OUTCOME IN PREGNANT WOMEN WITH CANCER Chemotherapy in pregnancy: from fetal safety to maternal efficacyFrom20 Sep 2017 → 16 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Live fluorescence imaging system in environmental controlled stable conditionsFrom1 Oct 2016 → 30 Sep 2018Funding: Fund Recuperation Fiscal Exemption
- Cancer and pregnancy: effects of prenatal exposure to cancer treatment on neurocognitive development: an MRI and ERP studyFrom1 Sep 2016 → 30 Sep 2022Funding: FWO fellowships
Publications
1 - 10 of 202
- Determining the exposure of maternal medicines through breastfeeding: the UmbrelLACT study protocol - A contribution from the ConcePTION project(2024)
Authors: Martje Van Neste, Nina Nauwelaerts, Michael Ceulemans, Kristel Van Calsteren, An Eerdekens, Pieter Annaert, Karel Allegaert, Anne Smits
- Results of an international survey on the current organization of care for pregnant women with cancer(2024)
Authors: Joosje Heimovaara, Kristel Van Calsteren, Frédéric Amant
- Evaluating offspring Genomic and Epigenomic alterations after prenatal exposure to Cancer treatment In Pregnancy (GE-CIP): a multicentric observational study.(2024)
Authors: Bernard Thienpont, Kristel Van Calsteren, Liesbeth Lenaerts, Frédéric Amant
Pages: e081833 - Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology.(2024)
Authors: Tatjana Jatsenko, Stefania Tuveri, Lore Lannoo, Kristel Van Calsteren, Liesbeth Lenaerts, Sabine Tejpar, Bernard Thienpont, Joris Vermeesch
Pages: 2220 - Reassuring pregnancy outcomes in women with mild COL4A3-5-related disease (Alport syndrome) and genetic type of disease can aid personalized counseling.(2024)
Authors: Kathleen Claes, Kristel Van Calsteren
Pages: S0085-2538 - Letter to the editor re Davis et al., 2023: BELpREG, the first of its kind real-world data source on medication use in pregnancy in Belgium(2024)
Authors: Michael Ceulemans, Laure Sillis, Karel Allegaert, Annick Bogaerts, Maarten De Vos, Titia Hompes, Anne Smits, Kristel Van Calsteren, Jan Verbakel, Veerle Foulon
- IMPLEMENTATION OF GENOME-WIDE CELL-FREE DNA SEQUENCING FOR THE EARLY IDENTIFICATION AND EFFICIENT MANAGEMENT OF HIGH-RISK PREGNANCIES(2023)
Authors: Lore Lannoo, Kristel Van Calsteren, Kris Van Den Bogaert, Koenraad Devriendt
- Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features(2023)
Authors: Beppe Floris, Kristel Van Calsteren, Patrick Neven, Sileny Han, Daniela Annibali, Diether Lambrechts, Liesbeth Lenaerts, Frédéric Amant
Pages: 3729 - 3743 - What helps define outcomes in persistent uninterpretable non-invasive prenatal testing: Maternal factors, fetal fraction or quality scores?(2023)
Authors: Lore Lannoo, Nathalie Brison, Kris Van Den Bogaert, Joris Vermeesch, Koenraad Devriendt, Kristel Van Calsteren
Pages: 1333 - 1343 - Cell-free DNA methylome analysis for early preeclampsia prediction(2023)
Authors: Marie De Borre, Lore Lannoo, Kobe De Ridder, Mio Aerden, Jeroen Breckpot, Koenraad Devriendt, Joris Vermeesch, Kristel Van Calsteren, Bernard Thienpont
Pages: 2206 - +
Patents
1 - 1 of 1
- Preeclampsia diagnosis (Inventor)